Ministry of Food and Drug Safety approves treatment for immune thrombocytopenia

News Healthcare & Pharma General Updates

Date: 20th Jan, 2025 Source: Korea Food and Drug Administration (KFDA) Country: South Korea Original Source

Brief

On 20/01/2025, the Korea Food and Drug Administration (KFDA) issued an update regarding "Ministry of Food and Drug Safety approves treatment for immune thrombocytopenia". The KFDA approved a rare disease treatment, Tavalisumab Injection 100mg (Poteligumab), for adult immune thrombocytopenia, providing new therapeutic opportunities for patients who previously showed inadequate responses to treatments. This approval is expected to expand treatment options for these patients.

This content is restricted.

Highlights content goes here...

This content is restricted.

Korea Food and Drug Administration (KFDA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Ministry of Food and Drug Safety approves treatment for immune thrombocytopenia

Brief

Korea Food and Drug Administration (KFDA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Ministry of Food and Drug Safety approves treatment for immune thrombocytopenia

Brief

Korea Food and Drug Administration (KFDA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.